Jason Martin

M & M Environmental Group LLC provides environmental services to oil and gas industry. It provides a range of services from spill containment and rig services to completions and disposal. The firm's services include rig services, trucking, disposal, completions, contract labor and sandblasting and painting services. It offers services to the steel, coal, construction and waste management industries. The company was founded by Sam McFadin in 2010 and is headquartered in Conway, AR.

Yulex Corp. manufactures and distributes specialty natural rubber materials to consumers and brands. Its products include Guayule, Russian Dandelion, and Yulex Pure. The company was founded by Daniel Swiger and Jeffrey A. Martin in 2000 and is headquartered in Phoenix, AZ.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

M & M Environmental Group LLC provides environmental services to oil and gas industry. It provides a range of services from spill containment and rig services to completions and disposal. The firm's services include rig services, trucking, disposal, completions, contract labor and sandblasting and painting services. It offers services to the steel, coal, construction and waste management industries. The company was founded by Sam McFadin in 2010 and is headquartered in Conway, AR.

Omega Capital Management LLC (Omega Capital Management) is a private equity firm subsidiary of Jason S. Martin Revocable Trust founded in 2013 by Jason S. Martin. The firm is headquarter in Tulsa, Oklahoma.

Luminus Devices, Inc. develops and manufactures solid state lighting solutions. Its products include COB arrays, mid power LEDs, XNOVA cube, high brightness white LEDs, color LEDs, color mix LEDs, UV LEDs, IR LEDs and horticulture LEDs. The company was founded by Alexei Erchak and John D. Joannopoulos in 2002 and is headquartered in Sunnyvale, CA.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Raisbeck Engineering, Inc. develops, markets and manufactures worldwide-certified performance improvement systems. The firm offers systems for the Beechcraft King Air, Bombardier Learjet and DeHaviland Twin Otter and also builds products for commercial aircraft. The company was founded by James D. Raisbeck and Sherry Raisbeck in 1982 and is headquartered in Seattle, WA.

Argonaut Private Equity LLC (Argonaut Private Equity) is a private equity firm founded in 2002 by Jason Martin and George B. Kaiser. The firm is headquartered in Tulsa, Oklahoma.

Argonaut Private Equity LLC (Argonaut Private Equity) is a private equity firm founded in 2002 by Jason Martin and George B. Kaiser. The firm is headquartered in Tulsa, Oklahoma.

Raisbeck Engineering, Inc. develops, markets and manufactures worldwide-certified performance improvement systems. The firm offers systems for the Beechcraft King Air, Bombardier Learjet and DeHaviland Twin Otter and also builds products for commercial aircraft. The company was founded by James D. Raisbeck and Sherry Raisbeck in 1982 and is headquartered in Seattle, WA.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Yulex Corp. manufactures and distributes specialty natural rubber materials to consumers and brands. Its products include Guayule, Russian Dandelion, and Yulex Pure. The company was founded by Daniel Swiger and Jeffrey A. Martin in 2000 and is headquartered in Phoenix, AZ.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Omega Capital Management LLC (Omega Capital Management) is a private equity firm subsidiary of Jason S. Martin Revocable Trust founded in 2013 by Jason S. Martin. The firm is headquarter in Tulsa, Oklahoma.

Raisbeck Engineering, Inc. develops, markets and manufactures worldwide-certified performance improvement systems. The firm offers systems for the Beechcraft King Air, Bombardier Learjet and DeHaviland Twin Otter and also builds products for commercial aircraft. The company was founded by James D. Raisbeck and Sherry Raisbeck in 1982 and is headquartered in Seattle, WA.

Omega Capital Management LLC (Omega Capital Management) is a private equity firm subsidiary of Jason S. Martin Revocable Trust founded in 2013 by Jason S. Martin. The firm is headquarter in Tulsa, Oklahoma.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Raisbeck Engineering, Inc. develops, markets and manufactures worldwide-certified performance improvement systems. The firm offers systems for the Beechcraft King Air, Bombardier Learjet and DeHaviland Twin Otter and also builds products for commercial aircraft. The company was founded by James D. Raisbeck and Sherry Raisbeck in 1982 and is headquartered in Seattle, WA.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Yulex Corp. manufactures and distributes specialty natural rubber materials to consumers and brands. Its products include Guayule, Russian Dandelion, and Yulex Pure. The company was founded by Daniel Swiger and Jeffrey A. Martin in 2000 and is headquartered in Phoenix, AZ.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Raisbeck Engineering, Inc. develops, markets and manufactures worldwide-certified performance improvement systems. The firm offers systems for the Beechcraft King Air, Bombardier Learjet and DeHaviland Twin Otter and also builds products for commercial aircraft. The company was founded by James D. Raisbeck and Sherry Raisbeck in 1982 and is headquartered in Seattle, WA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Omega Capital Management LLC (Omega Capital Management) is a private equity firm subsidiary of Jason S. Martin Revocable Trust founded in 2013 by Jason S. Martin. The firm is headquarter in Tulsa, Oklahoma.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Argonaut Private Equity LLC (Argonaut Private Equity) is a private equity firm founded in 2002 by Jason Martin and George B. Kaiser. The firm is headquartered in Tulsa, Oklahoma.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Luminus Devices, Inc. develops and manufactures solid state lighting solutions. Its products include COB arrays, mid power LEDs, XNOVA cube, high brightness white LEDs, color LEDs, color mix LEDs, UV LEDs, IR LEDs and horticulture LEDs. The company was founded by Alexei Erchak and John D. Joannopoulos in 2002 and is headquartered in Sunnyvale, CA.

Omega Capital Management LLC (Omega Capital Management) is a private equity firm subsidiary of Jason S. Martin Revocable Trust founded in 2013 by Jason S. Martin. The firm is headquarter in Tulsa, Oklahoma.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Omega Capital Management LLC (Omega Capital Management) is a private equity firm subsidiary of Jason S. Martin Revocable Trust founded in 2013 by Jason S. Martin. The firm is headquarter in Tulsa, Oklahoma.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Argonaut Private Equity LLC (Argonaut Private Equity) is a private equity firm founded in 2002 by Jason Martin and George B. Kaiser. The firm is headquartered in Tulsa, Oklahoma.

Voice Signal Technologies, Inc. develops software for mobile handsets. It provides speech solutions for consumer products and mobile devices. The company's solutions offer speech capabilities, including speaker-independent name dialing and contact lookup, vocabulary dictation, email and SMS messaging. VoiceSignal Technologies was founded by Daniel Roth and Thomas Lazay in 1995 and is headquartered in Woburn, MA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.

Enterprise Investors Sp zoo (Enterprise Investors) is a private equity firm founded in 1990 by John Birkelund and Robert Faris. The firm is headquartered in Warsaw, Poland.